Track loss of exclusivity across FDA-approved drugs — when each product's patents and exclusivity lapse — joined to the company graph, so you can see the cliff and the company behind it. Built from public FDA Orange Book data.
Every FDA-approved drug ordered by when its protection lapses — the patent cliff, soonest first.
The full set of Orange Book patents and regulatory exclusivities behind each product, with expiry dates.
Roll cliffs up to the applicant company — which firms face a wave of expiries, and when.
When exclusivity clears the way for generic or biosimilar entry — the opening competitors wait for.
PDUFA dates, advisory committees and trial readouts from ClinicalTrials.gov and openFDA.
Follow companies or drugs and get notified as new expiries and catalysts land.
Readout = trial primary-completion estimate from ClinicalTrials.gov — a forward indicator, not a confirmed FDA action date.